Cavitary pulmonary disease in a patient treated with natalizumab

Presse Med. 2014 Sep;43(9):1009-12. doi: 10.1016/j.lpm.2013.12.012. Epub 2014 Apr 16.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antitubercular Agents / therapeutic use
  • Clarithromycin / therapeutic use
  • Ethambutol / therapeutic use
  • Female
  • Humans
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Mycobacterium avium Complex
  • Mycobacterium avium-intracellulare Infection / diagnosis*
  • Mycobacterium avium-intracellulare Infection / drug therapy
  • Natalizumab
  • Pneumonia, Bacterial / drug therapy
  • Pneumonia, Bacterial / microbiology*

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal, Humanized
  • Antitubercular Agents
  • Natalizumab
  • Ethambutol
  • Clarithromycin